Last reviewed · How we verify
Kenalog and Sensorcaine
Kenalog and Sensorcaine is a Corticosteroid + Local anesthetic combination Small molecule drug developed by Horizon Health Network. It is currently in Phase 3 development for Intra-articular injection for inflammatory joint conditions (e.g., rheumatoid arthritis, osteoarthritis), Soft-tissue injection for localized inflammation and pain relief. Also known as: Kenalog, Triamcinolone, Sensorcaine, Marcaine.
This is a combination of a corticosteroid (triamcinolone acetonide) and a local anesthetic (bupivacaine) for intra-articular or soft-tissue injection to reduce inflammation and provide pain relief.
Kenalog and Sensorcaine are used in a peripheral nerve block, specifically in a treatment for medication overuse headaches, as part of a clinical trial comparing its effects to Topamax.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Kenalog and Sensorcaine |
|---|---|
| Also known as | Kenalog, Triamcinolone, Sensorcaine, Marcaine, Bupivacaine hydrochloride |
| Sponsor | Horizon Health Network |
| Drug class | Corticosteroid + Local anesthetic combination |
| Target | Glucocorticoid receptor (triamcinolone); Voltage-gated sodium channels (bupivacaine) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management / Orthopedics |
| Phase | Phase 3 |
Mechanism of action
Kenalog (triamcinolone acetonide) is a synthetic corticosteroid that suppresses local inflammatory responses by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene production. Sensorcaine (bupivacaine) is a long-acting amide local anesthetic that blocks sodium channels in nerve membranes, preventing depolarization and pain signal transmission. Together, they provide both anti-inflammatory and analgesic effects at the injection site.
Approved indications
- Intra-articular injection for inflammatory joint conditions (e.g., rheumatoid arthritis, osteoarthritis)
- Soft-tissue injection for localized inflammation and pain relief
Common side effects
- Local injection site reactions (pain, swelling, erythema)
- Transient increase in joint pain (post-injection flare)
- Infection at injection site
- Systemic corticosteroid effects (with repeated injections)
Key clinical trials
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study (NA)
- Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery (PHASE2)
- Corticosteroid Injection Versus Nerve Block (NA)
- Effect of Addition of Steroids on Duration of Analgesia (EARLY_PHASE1)
- Phenol Neurolysis Versus Local Anesthetic Plus Steroid Genicular Nerve Block in Knee Osteoarthritis
- Plantar Fasciitis Randomized Clinical Control Trial (NA)
- Ultrasound-Guided Corticosteroid and Bupivacaine for Facial Nerve Function and Thickness in Bell's Palsy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kenalog and Sensorcaine CI brief — competitive landscape report
- Kenalog and Sensorcaine updates RSS · CI watch RSS
- Horizon Health Network portfolio CI
Frequently asked questions about Kenalog and Sensorcaine
What is Kenalog and Sensorcaine?
How does Kenalog and Sensorcaine work?
What is Kenalog and Sensorcaine used for?
Who makes Kenalog and Sensorcaine?
Is Kenalog and Sensorcaine also known as anything else?
What drug class is Kenalog and Sensorcaine in?
What development phase is Kenalog and Sensorcaine in?
What are the side effects of Kenalog and Sensorcaine?
What does Kenalog and Sensorcaine target?
Related
- Drug class: All Corticosteroid + Local anesthetic combination drugs
- Target: All drugs targeting Glucocorticoid receptor (triamcinolone); Voltage-gated sodium channels (bupivacaine)
- Manufacturer: Horizon Health Network — full pipeline
- Therapeutic area: All drugs in Rheumatology / Pain Management / Orthopedics
- Indication: Drugs for Intra-articular injection for inflammatory joint conditions (e.g., rheumatoid arthritis, osteoarthritis)
- Indication: Drugs for Soft-tissue injection for localized inflammation and pain relief
- Also known as: Kenalog, Triamcinolone, Sensorcaine, Marcaine, Bupivacaine hydrochloride
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing